{
    "symbol": "ACHV",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 20:14:07",
    "content": " Our cash forecast includes reimbursements from the awarded $2.5 million grant, received from the NIH to support the Phase 2 ORCA-V1 trial, to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. We won't have enough efficacy, because that's a small Phase II, but what we would be doing is discussing with the FDA after we get approval for smoking cessation that we would only need to have one Phase III study to add then vaping onto the indication in the label."
}